TY - JOUR
T1 - Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia
AU - Itahashi, Takashi
AU - Noda, Yoshihiro
AU - Iwata, Yusuke
AU - Tarumi, Ryosuke
AU - Tsugawa, Sakiko
AU - Plitman, Eric
AU - Honda, Shiori
AU - Caravaggio, Fernando
AU - Kim, Julia
AU - Matsushita, Karin
AU - Gerretsen, Philip
AU - Uchida, Hiroyuki
AU - Remington, Gary
AU - Mimura, Masaru
AU - Aoki, Yuta Y.
AU - Graff-Guerrero, Ariel
AU - Nakajima, Shinichiro
N1 - Funding Information:
Canadian Institutes of Health Research: MOP-141968 (AG-G), MOP 142493 (AG-G). Ministry of Economic Development and Innovation Ontario (AG-G). Ontario Mental Health Foundation Type A grant (AG-G). NARSAD Independent Investigator (AGG). Y.N. has received a Grant-in-Aid for Young Scientists and Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (JSPS), research grants from Japan Agency for Medical Research and Development (AMED), investigator-initiated clinical study grants from TEIJIN PHARMA LIMITED and Inter Reha Co., Ltd. Y.N. also receives research grants from Mochida Memorial Foundation for Medical and Pharmaceutical Research and Daiichi Sankyo Scholarship Donation Program. Y.N. has received speaker’s honoraria from Dainippon Sumitomo Pharma within the past three years. Y.N. also receives equipment-in-kind support for an investigator-initiated study from Magventure Inc, Inter Reha Co., Ltd., BrainBox Ltd., and Miyuki Giken Co., Ltd. S.N. has received a Grant-in-Aid for Young Scientists A and Grants-in-Aid for Scientific Research B and C from JSPS, and research grants from Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, and Daiichi Sankyo Scholarship Donation Program within the past three years. S.N. has also received research support, manuscript fees, or speaker’s honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceu-tical, Shionogi, and Yoshitomi Yakuhin within the past three years. M.M. received grants and/or speaker’s honoraria from Asahi Kasei Pharma, Astellas Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, FujiFilm RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, Merck Sharp and Dohme, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, and Yoshitomi Yakuhin. H.U. has received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Daiichi Sankyo Company, Mochida Pharmaceutical, and Meiji-Seika Pharma; speaker’s honoraria from Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Eisai, and Meiji-Seika Pharma; and advisory panel payments from Dainippon-Sumitomo Pharma within the past three years. T.I. has received a Grants-in-Aid for Scientific Research C (19K03370) from JSPS. Y.Y.A. has received a Grant-in-Aid for Young Scientists (21K15719) from JSPS.
Funding Information:
Canadian Institutes of Health Research: MOP-141968 (AG-G), MOP 142493 (AG-G). Ministry of Economic Development and Innovation Ontario (AG-G). Ontario Mental Health Foundation Type A grant (AG-G). NARSAD Independent Investigator (AGG). Y.N. has received a Grant-in-Aid for Young Scientists and Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (JSPS), research grants from Japan Agency for Medical Research and Development (AMED), investigator-initiated clinical study grants from TEIJIN PHARMA LIMITED and Inter Reha Co. Ltd. Y.N. also receives research grants from Mochida Memorial Foundation for Medical and Pharmaceutical Research and Daiichi Sankyo Scholarship Donation Program. Y.N. has received speaker's honoraria from Dainippon Sumitomo Pharma within the past three years. Y.N. also receives equipment-in-kind support for an investigator-initiated study from Magventure Inc, Inter Reha Co. Ltd. BrainBox Ltd. and Miyuki Giken Co. Ltd. S.N. has received a Grant-in-Aid for Young Scientists A and Grants-in-Aid for Scientific Research B and C from JSPS, and research grants from Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, and Daiichi Sankyo Scholarship Donation Program within the past three years. S.N. has also received research support, manuscript fees, or speaker's honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceu-tical, Shionogi, and Yoshitomi Yakuhin within the past three years. M.M. received grants and/or speaker's honoraria from Asahi Kasei Pharma, Astellas Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, FujiFilm RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, Merck Sharp and Dohme, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, and Yoshitomi Yakuhin. H.U. has received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Daiichi Sankyo Company, Mochida Pharmaceutical, and Meiji-Seika Pharma; speaker's honoraria from Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Eisai, and Meiji-Seika Pharma; and advisory panel payments from Dainippon-Sumitomo Pharma within the past three years. T.I. has received a Grants-in-Aid for Scientific Research C (19K03370) from JSPS. Y.Y.A. has received a Grant-in-Aid for Young Scientists (21K15719) from JSPS.
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/1
Y1 - 2021/1
N2 - Background: One-third of patients with schizophrenia are treatment-resistant to non-clozapine antipsychotics (TRS), while the rest respond (NTRS). Examining whether TRS and NTRS represent different pathophysiologies is an important step toward precision medicine. Methods: Focusing on cortical thickness (CT), we analyzed international multi-site cross-sectional datasets of magnetic resonance imaging comprising 110 patients with schizophrenia (NTRS = 46, TRS = 64) and 52 healthy controls (HCs). We utilized a logistic regression with L1-norm regularization to find brain regions related to either NTRS or TRS. We conducted nested 10-fold cross-validation and computed the accuracy and area under the curve (AUC). Then, we applied the NTRS classifier to patients with TRS, and vice versa. Results: Patients with NTRS and TRS were classified from HCs with 65% and 78% accuracies and with the AUC of 0.69 and 0.85 (p = 0.014 and < 0.001, corrected), respectively. The left planum temporale (PT) and left anterior insula/inferior frontal gyrus (IFG) contributed to both NTRS and TRS classifiers. The left supramarginal gyrus only contributed to NTRS and right superior temporal sulcus and right lateral orbitofrontal cortex only to the TRS. The NTRS classifiers successfully distinguished those with TRS from HCs with the AUC of 0.78 (p < 0.001), while the TRS classifiers classified those with NTRS from HCs with the AUC of 0.69 (p = 0.015). Conclusion: Both NTRS and TRS could be distinguished from HCs on the basis of CT. The CT pathological basis of NTRS and TRS has commonalities, and TRS presents unique CT features.
AB - Background: One-third of patients with schizophrenia are treatment-resistant to non-clozapine antipsychotics (TRS), while the rest respond (NTRS). Examining whether TRS and NTRS represent different pathophysiologies is an important step toward precision medicine. Methods: Focusing on cortical thickness (CT), we analyzed international multi-site cross-sectional datasets of magnetic resonance imaging comprising 110 patients with schizophrenia (NTRS = 46, TRS = 64) and 52 healthy controls (HCs). We utilized a logistic regression with L1-norm regularization to find brain regions related to either NTRS or TRS. We conducted nested 10-fold cross-validation and computed the accuracy and area under the curve (AUC). Then, we applied the NTRS classifier to patients with TRS, and vice versa. Results: Patients with NTRS and TRS were classified from HCs with 65% and 78% accuracies and with the AUC of 0.69 and 0.85 (p = 0.014 and < 0.001, corrected), respectively. The left planum temporale (PT) and left anterior insula/inferior frontal gyrus (IFG) contributed to both NTRS and TRS classifiers. The left supramarginal gyrus only contributed to NTRS and right superior temporal sulcus and right lateral orbitofrontal cortex only to the TRS. The NTRS classifiers successfully distinguished those with TRS from HCs with the AUC of 0.78 (p < 0.001), while the TRS classifiers classified those with NTRS from HCs with the AUC of 0.69 (p = 0.015). Conclusion: Both NTRS and TRS could be distinguished from HCs on the basis of CT. The CT pathological basis of NTRS and TRS has commonalities, and TRS presents unique CT features.
KW - Classification
KW - Cortical thickness
KW - Schizophrenia
KW - Treatment-resistant
UR - http://www.scopus.com/inward/record.url?scp=85118809287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118809287&partnerID=8YFLogxK
U2 - 10.1016/j.nicl.2021.102852
DO - 10.1016/j.nicl.2021.102852
M3 - Article
C2 - 34638035
AN - SCOPUS:85118809287
SN - 2213-1582
VL - 32
JO - NeuroImage: Clinical
JF - NeuroImage: Clinical
M1 - 102852
ER -